Home › Funds › Merck & Co., Inc. › MRNA
Merck & Co., Inc. position in MRNA
MODERNA INC · Health Care
Merck & Co., Inc. reported holding 2,308,190 shares of MRNA (MODERNA INC) in its Q3 2026 13F filing — a position valued at US$444.5M, representing 54.18% of its reported portfolio and ranking #1 among its reported holdings. Merck & Co., Inc. has disclosed MRNA holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s MRNA position evolved
Merck & Co., Inc. first disclosed a stake in MRNA in Q4 2024 at 2,308,190 shares (US$96.0M). The position peaked in Q3 2026 at 2,308,190 shares, worth US$444.5M. Across 8 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,308,190 shares valued at US$444.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 2.31M | $95.97M | New |
| Q1 2025 | 2.31M | $65.44M | Hold |
| Q2 2025 | 2.31M | $63.68M | Hold |
| Q3 2025 | 2.31M | $59.62M | Hold |
| Q4 2025 | 2.31M | $68.07M | Hold |
| Q1 2026 | 2.31M | $117.26M | Hold |
| Q2 2026 | 2.31M | $161.64M | Hold |
| Q3 2026 | 2.31M | $444.49M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRNA and 13F data
MRNA (MODERNA INC) is a Health Care company. 41 other funds we track also report a position in MRNA — the largest reported positions include Fidelity Management & Research (FMR) (US$11.35B), Capital World Investors (US$4.36B), Baillie Gifford & Co (US$2.20B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRNA
- Fidelity Management & Research (FMR) 58.96M sh · $11.35B · Q3 2026
- Capital World Investors 22.64M sh · $4.36B · Q3 2026
- Baillie Gifford & Co 11.44M sh · $2.20B · Q3 2026
- Theleme Partners LLP 6.66M sh · $1.28B · Q3 2026
- IMC-Chicago, LLC 3.07M sh · $590.92M · Q3 2026
- BANQUE PICTET & CIE SA 2.15M sh · $414.27M · Q3 2026
- Flagship Pioneering, LLC 4.63M sh · $324.39M · Q2 2026
- a16z Perennial Management, L.P. 1.52M sh · $292.57M · Q3 2026
- Douglas Lane & Associates, LLC 1.16M sh · $223.56M · Q3 2026
- Beau Ventures, LLc 1.00M sh · $192.58M · Q3 2026
- Lingotto Investment Management LLP 749.21K sh · $144.27M · Q3 2026
- Baron Funds 1.99M sh · $139.32M · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held MRNA?
Merck & Co., Inc. has disclosed MRNA holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Merck & Co., Inc.'s current position in MRNA?
As of Q3 2026, Merck & Co., Inc. holds 2.31M shares of MRNA (MODERNA INC), valued at $444.49M, representing 54.18% of its reported portfolio and ranking #1.
Has Merck & Co., Inc. been buying or selling MRNA?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in MRNA. The position peaked in Q3 2026 at 2.31M shares.
Which other funds hold MRNA?
Other major institutional holders of MRNA include Fidelity Management & Research (FMR), Capital World Investors, Baillie Gifford & Co, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.